Title: TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.
Journal: Molecular cancer therapeutics 20120301
1137868-96-2
1062243-51-9
2108449-45-0
114077-82-6 | 4-Chloropyridine-3-carboxaldehyde | AA000AEG | MFCD04112523
114322-14-4 | 2,1,3-Benzoxadiazole-4-sulfonyl chloride | AA000AZS | MFCD00068072
1160474-68-9 | Benzenemethanol, 2,5-difluoro-4-nitro- | AA000BE9 | MFCD09909606
116209-27-9 | 3-Methoxy-4-(pyrrolidin-1-yl)benzaldehyde | AA000BVA | MFCD07403409
116460-89-0 | Ethyl 3-(4-cyanophenyl)propanoate | AA000CGX | MFCD08234822
1167056-36-1 | Ethyl 1h-pyrrolo[3,2-c]pyridine-4-carboxylate | AA000D0E | MFCD11845588
117-82-8 | 1,2-Benzenedicarboxylic acid, 1,2-bis(2-methoxyethyl) ester | AA000DFE | MFCD00042842
1171611-95-2 | 4-Hydrazino-6-methoxy-2-methylquinoline hydrochloride | AA000DQ8 | MFCD09997977
1173019-42-5 | RAC CARPROFEN-D3 | AA000DZY | MFCD09840202
117483-89-3 | 1-((Benzyloxy)carbonyl)indoline-2-carboxylic acid | AA000E9L | MFCD02682032